In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has ...
Last year, the board voted to deem Enbrel “unaffordable,” setting up a months-long process of determining whether it should ...
Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...
Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.
AbbVie is on the rebound after a sell-off on concerns about the pending FDA decision for a biosimilar drug. Humira and Enbrel are among the top-selling drugs to be copycatted but biosimilars are ...
In a first-in-the-nation move, a Colorado panel voted to limit what health plans in the state will pay for a costly arthritis ...
Non-medical switching policies that mandate biosimilar use for inflammatory arthritis do not appear to increase the use of ...
Upper payment limits (UPL) present clear challenges and dangers to patients because of its potential impact on access to life ...
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback